Here's Why Unity Biotechnology Is Getting Crushed Today
The development-stage biopharma announced disappointing results from a clinical trial.
Unity Biotechnology, Inc.(UBX)
Nasdaq Global Select
UBX
$0.84
-$0.01
-1.2%
Price as of May 18, 2022, 9:50 a.m. ET
View Interactive UBX Charts
Unity Biotechnology, Inc.
Interactive Chart
Compare UBX Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
UBX
Unity Biotechnology, Inc.
|
$0.85 | $59M | -80.6% | |
|
CWBHF |
$0.49 | $72M | -85.3% | |
|
CNTTQ |
$0.05 | $7M | -91.8% | |
|
XLY |
$0.14 | $138M | -51.6% | -88.7% |
|
PANC.DL |
$0.00 | $53 | -99.9% | -99.9% |
News & Analysis: Unity Biotechnology, Inc.
Unity Biotech: Buy at the Low?
Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?
Here's Why Unity Biotechnology Dropped as Much as 20.4% Today
The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.
